



# SUDARSHAN PHARMA INDUSTRIES LTD

Head Office : 301, Aura Biplax, Premium Retail, Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092.

E-mail : [compliance@sudarshanpharma.com](mailto:compliance@sudarshanpharma.com), Website : [www.sudarshanpharma.com](http://www.sudarshanpharma.com)

Board Line : +91-22-42221111 / 43331111/42221116 (100 line) CIN: L51496MH2008PLC184997

SPIL/CS/SE/2025-2026/49

Date: 8<sup>th</sup> September 2025

To,  
The Listing Department  
BSE Limited  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400 001

BSE Scrip Code: 543828  
BSE Trading Symbol: SUDARSHAN  
ISIN: INE00TV01023

**Sub: Submission of Media Release titled “Sudarshan Pharma boosts Manufacturing Capacity with Strategic Investment in Operational API Facility; Signs Definitive Agreement with Srigen Lifesciences”**

**Ref: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Dear Sir / Madam,

In continuation of our earlier intimation dated August 14, 2025 (Ref: SPIL/CS/SE/2025-2026/47), please find enclosed herewith a copy of the Media Release titled “Sudarshan Pharma boosts Manufacturing Capacity with Strategic Investment in Operational API Facility for Rs.25,50,00,000/-; Signs Definitive Agreement with Srigen Lifesciences” for public dissemination.

We request you to take the above information on record and treat this as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Request you to take the same on your record.

Thanks & Regards,

Yours faithfully,

For, **Sudarshan Pharma Industries Limited**

  
Hemal Mehta  
Chairman & Managing Director





# SUDARSHAN PHARMA INDUSTRIES LTD

Head Office : 301, Aura Biplax, Premium Retail, Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092.

E-mail : [compliance@sudarshanpharma.com](mailto:compliance@sudarshanpharma.com), Website : [www.sudarshanpharma.com](http://www.sudarshanpharma.com)

Board Line : +91-22-42221111 / 43331111/42221116 (100 line) CIN: L51496MH2008PLC184997

## Media Release

Sudarshan Pharma boosts Manufacturing Capacity with Strategic Investment in Operational API Facility; Signs Definitive Agreement with Srigen Lifesciences

**Mumbai, September 8, 2025:** Sudarshan Pharma Industries Limited (SPIL) is pleased to announce a significant strategic capex investment consequent to a definitive agreement with Srigen Lifesciences Private Limited (Srigen) an API Manufacturing company, for the transfer of capital assets—comprising land, building, and plant & machinery—at a fully operational manufacturing facility located at a strategic location in Telangana – 501401 at a consideration of Rs.25,50,00,000/- (Rupees Twenty Five Crores And Fifty Lakhs only).

This high-impact move will result into massive growth in SPIL's manufacturing capacity and will substantially accelerate its trajectory in the high-growth Active Pharmaceutical Ingredients (API) and specialty chemicals sectors, resulting into incremental footprint in the domestic and global market. The transaction forms a cornerstone of SPIL's long-term strategy to build a robust, scalable, and compliance-driven manufacturing infrastructure to support global expansion and drive sustained value creation for stakeholders.

The investment—valued at ₹255 million—reflects SPIL's commitment to vertical integration, operational efficiency, and product diversification. The acquired facility will be utilized for the production of high-value, technically complex pharmaceutical ingredients including Ropivacaine, Bupivacaine, Probenecid (Probalan), Sitagliptin, Apixaban, and Rivaroxaban—critical APIs and intermediates with strong demand across regulated and semi-regulated markets.

### Strategic Rationale and Benefits

**Immediate Manufacturing Scale-Up:** The facility adds instant production capacity, accelerating supply chain responsiveness and overall throughput.

**Faster Time-to-Market:** With infrastructure and regulatory frameworks already established, SPIL can significantly reduce product launch timelines compared to greenfield projects.

**Expanded Product Portfolio:** The facility is capable of producing complex, high-margin molecules, further enhancing SPIL's offerings in global therapeutic markets.

**Regulatory Advantage:** The facility's proven compliance track record and comprehensive regulatory documentation are expected to shorten approval cycles and lower regulatory costs.

### Executive Commentary

Sachin Mehta, Joint Managing Director & Chief Financial Officer, SPIL, commented:

"This investment represents a pivotal milestone in Sudarshan Pharma's growth agenda. It not only strengthens our manufacturing backbone but also significantly enhances our ability to serve global markets with agility, quality, and regulatory compliance. This addition is expected to contribute meaningfully to both revenue and profitability, supporting stronger financial performance and long-term shareholder value creation."





# SUDARSHAN PHARMA INDUSTRIES LTD

**Head Office :** 301, Aura Biplax, Premium Retail, Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092.

**E-mail :** [compliance@sudarshanpharma.com](mailto:compliance@sudarshanpharma.com), **Website :** [www.sudarshanpharma.com](http://www.sudarshanpharma.com)

**Board Line :** +91-22-42221111 / 43331111/42221116 (100 line) **CIN:** L51496MH2008PLC184997

## About Srigen Lifesciences Private Limited

Established in 2010, Srigen Lifesciences Private Limited is a research-driven pharmaceutical company specializing in the development, manufacturing, and commercialization of advanced API Key Starting Materials (KSMs) and intermediates. The company operates a well-equipped facility with 80-kilolitre reactor capacity, supporting medium- to large-scale, multi-product manufacturing under stringent quality, safety, and regulatory standards.

Srigen has successfully developed and commercialized over 50 KSMs and intermediates, many of which are patent-protected and supported by detailed regulatory filings. Its key product portfolio includes Molnupiravir Sodium Intermediate, Mirabegron Intermediate, Glimepiride KSM, Vildagliptin KSM, Sitagliptin KSM and Dabigatran Etxilate Mesylate Intermediate.

The Company has established long-standing partnerships with leading pharmaceutical firms including Sai Life Sciences, Neuland Laboratories, DIVIS Laboratories, Aurobindo Pharma, SMS Pharmaceuticals, and Kesava Organics, reinforcing its position as a trusted manufacturing partner in the global API and KSM value chain.

## About Sudarshan Pharma Industries Limited (SPIL)

Sudarshan Pharma Industries Limited (SPIL) is a Mumbai-based pharmaceutical and specialty chemical company engaged in the manufacturing, marketing, and distribution of Active Pharmaceutical Ingredients (APIs), intermediates, specialty chemicals, and finished formulations. With a strong presence in both domestic and international markets, SPIL offers over 150 products across various therapeutic and industrial segments. The company operates state-of-the-art, GMP-compliant manufacturing facilities in Maharashtra and Gujarat, supported by in-house R&D and a robust quality control framework. SPIL also provides contract manufacturing, private labelling, and formulation development services to leading pharma companies. Committed to quality, innovation, and regulatory compliance, SPIL continues to drive sustainable growth and global expansion.

